pediatric-obesity-intervention-selector

Pediatric Obesity: Intervention Selector

Step-by-step guide to selecting the appropriate intervention tier for a child (0–18 years) with obesity. Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456).

---

Step 1 — Gather Key Information

Before recommending anything, confirm:

• Age (years)
• BMI z-score (BMIz) using WHO growth charts for Canada
• What has already been tried (duration, adherence, response)
• Comorbidities (metabolic, mechanical, mental health — see 4Ms below)
• Family preferences and values — what outcomes matter most to them?
• Social determinants (food security, neighbourhood, family dynamics)

⚠️ Use person-first, neutral language throughout. Say "child with obesity" not "obese child." Refer to BMI, weight, or growth — not "fat" or "overweight."

---

Step 2 — First-Line: Behavioural & Psychological Interventions

All children with obesity, regardless of age. Strong recommendation, very low to moderate certainty.

Recommend a multicomponent intervention — must include at least 2 of:

• Physical activity
• Nutrition counselling
• Psychological support (e.g., CBT, motivational interviewing)
• Technology-assisted components (optional; weak evidence)

Individual components alone (nutrition-only, exercise-only) are conditional recommendations with weaker evidence — prefer multicomponent.

Practical targets:

• Higher-intensity sessions (aerobic + resistance training) superior to low-intensity
• Goal-setting, self-monitoring, problem-solving, and relapse prevention are effective behaviour change tools
• At least 26 hours of contact time improves outcomes
• Long-term support is essential — obesity is chronic and relapsing

Technology interventions alone: Neither for nor against (insufficient evidence).

---

Step 3 — Escalate to Pharmacotherapy?

Consider if: inadequate response to behavioural/psychological interventions AND age ≥ 12 years.

⚠️ No stepwise requirement — pharmacotherapy can be offered alongside, not only after, behavioural therapy. It must always be combined with behavioural/psychological interventions.

→ Go to the Pharmacotherapy Selector skill for agent selection.

If age < 12: insufficient evidence for any pharmacotherapy — do not prescribe.

---

Step 4 — Escalate to Surgery?

Consider if: age ≥ 13 years AND deemed eligible after comprehensive multidisciplinary assessment.

⚠️ Surgery does not require prior failure of pharmacotherapy. Consider based on severity, comorbidities, family preference, and centre availability.

Surgical options: Laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB). Both: conditional recommendation, low to moderate certainty.

Requirements before referral:

• Specialized, multidisciplinary team assessment
• Psychological/psychiatric clearance
• Nutritional assessment
• Family/caregiver involvement and support
• Shared decision-making about serious AE risk

→ Go to the Surgical Eligibility Screener skill for full checklist.

---

Step 5 — Shared Decision-Making at Every Tier

At every tier, the conversation matters as much as the prescription:

• Present all options (behavioural, pharmacologic, surgical) — no option should be withheld from discussion
• Acknowledge the balance of benefits and harms for each option
• Align on what success looks like — HRQoL, mood, mobility, not just BMI
• Involve both child and caregiver in the decision (separately if helpful)
• Address social determinants that may affect access or adherence
• Refer to multidisciplinary team where available

---

Clinical Guardrails

• Eating disorder vigilance: Ask about binge eating, body image concerns, atypical anorexia — especially before pharmacotherapy or surgery. Refer to specialist if suspected.
• Don't focus solely on weight. Improved HRQoL, depression, anxiety, and cardiometabolic markers are equally valid outcomes.
• Obesity is not a personal failing. Genetics, physiology, and environment drive it. Frame this clearly for families.
• Lipase inhibitors (orlistat): Suggested but not preferred — higher GI side effects and serious AE risk. Use only if GLP-1RA and metformin unavailable.
• Technology-only interventions: Insufficient evidence — do not use as a standalone strategy.

---

Source

CMAJ 2025 Clinical Practice Guideline: Managing obesity in children. Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: 10.1503/cmaj.241456 Updated version: June 3, 2025.